- The European Union has approved AstraZeneca plc’s AZN Forxiga (dapagliflozin) for chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D).
- Forxiga is a sodium-glucose cotransporter 2 (SGLT2) inhibitor.
- The approval is based on positive results from the DAPA-CKD Phase III trial that demonstrated that Forxiga, on top of standard-of-care (SoC) treatment, reduced the relative risk of worsening of renal function, the onset of end-stage kidney disease, or risk of cardiovascular or renal death by 39%, compared to placebo.
- Forxiga also significantly reduced the relative risk of death from any cause by 31% compared to placebo.
- Price Action: AZN stock is up 0.18% at $56.54 during the market session on the last check Monday.
- Related content: Benzinga's Full FDA Calendar.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
